Effects of corticosteroid use on readmission in obstructive lung disease

Respiratory Medicine

Volumn 104, Issue 2, 2010, Pages 211-218

  Velthove, Karin J ^a,b   Souverein, Patrick C ^a   van Solinge, Wouter W ^a,b   Leufkens, Hubert G M ^a   Lammers, Jan Willem J ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Corticosteroid; Exacerbation; ICS; Obstructive lung disease; Readmission

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; PREDNISONE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY LIVING; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE EXACERBATION; DRUG EFFECT; DRUG MEGADOSE; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION; ADOLESCENT; AGED; DISEASE COURSE; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES, OBSTRUCTIVE; MEDICATION COMPLIANCE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; PATIENT READMISSION; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 73749084613     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.08.014     Document Type: Article

References (46)

1. From the global strategy for the diagnosis management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: (2008). http://www.goldcopd.org
2. From the global strategy for asthma management and prevention. Global Initiative for Asthma (GINA). Available from: (2008). http://www.ginasthma.org
3. Halbert R.J., Natoli J.L., Gano A., Badamgarav E., Buist A.S., and Mannino D.M. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28 (2006) 523-532
4. Siva R., Green R.H., Brightling C.E., et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 29 (2007) 906-913
5. Tattersfield A., Knox A., Britton J., and Hall I. Asthma. Lancet 360 (2002) 1313-1322
6. Robinson D., Campbell D., Durham S., Pfeffer J., Barnes P., and Chung K. Systematic assessment of difficult-to-treat asthma. Eur Respir J 22 (2003) 478-483
7. O'Byrne P.M., Pedersen S., Lamm C.J., Tan W.C., and Busse W.W. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 179 (2009) 19-24
8. Vermeire P., Rabe K., Soriano J., and Maier W. Asthma control and differences in management practices across seven European countries. Respir Med 96 (2002) 142-149
9. Sullivan S.D., Rasouliyan L., Russo P.A., Kamath T., and Chipps B.E. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 62 (2007) 126-133
10. McKnight J., Scott A., Menzies D., Bourbeau J., Blais L., and Lemière C. A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J Clin Epidemiol 58 (2005) 206-208
11. Miller M.K., Lee J.H., Blanc P.D., et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 28 (2006) 1145-1155
12. Ekberg-Aronsson M., Lofdahl K., Nilsson J.A., Lofdahl C.G., and Nilsson P.M. Hospital admission rates among men and women with symptoms of chronic bronchitis and airflow limitation corresponding to the GOLD stages of chronic obstructive pulmonary disease - a population-based study. Respir Med 102 (2008) 109-120
13. Blais L., Ernst P., Boivin J.F., and Suissa S. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 158 (1998) 126-132
14. Gerrits C.M., Herings R.M., Leufkens H.G., and Lammers J.W. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 795-798
15. Herings R.M., Bakker A., Stricker B.H., and Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 46 (1992) 136-140
16. Kiri V.A., Bettoncelli G., Testi R., and Viegi G. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. Respir Med 99 (2005) 1115-1124
17. Roede B.M., Bresser P., Bindels P.J., et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 63 (2008) 968-973
18. Blais L., Suissa S., Boivin J.F., and Ernst P. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax 53 (1998) 1025-1029
19. Suissa S., Ernst P., and Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 57 (2002) 880-884
20. Rice K.L., Rubins J.B., Lebahn F., et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med 162 (2000) 174-178
21. Gerrits C.M., Herings R.M., Leufkens H.G., and Lammers J.W. Asthma exacerbations during first therapy with long acting beta 2-agonists. Pharm World Sci 21 (1999) 116-119
22. Breekveldt-Postma N.S., Erkens J.A., Aalbers R., van de Ven M.J., Lammers J.W., and Herings R.M. Extent of uncontrolled disease and associated medical costs in severe asthma - a PHARMO study. Curr Med Res Opin 24 (2008) 975-983
23. Van Ganse E., Van der Linden P.D., Leufkens H.G., Herings R.M., Vincken W., and Ernst P. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J 8 (1995) 1856-1860
24. Breekveldt-Postma N.S., Gerrits C.M., Lammers J.W., Raaijmakers J.A., and Herings R.M. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 98 (2004) 752-759
25. Ten Brinke A., Sterk P., Masclee A., et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 26 (2005) 812-818
26. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 45 (1992) 197-203
27. Malfertheiner P., and Hallerback B. Clinical manifestations and complications of gastroesophageal reflux disease (GERD). Int J Clin Pract 59 (2005) 346-355
28. Menckeberg T.T., Belitser S.V., Bouvy M.L., et al. Distinguishing patterns in the dynamics of long-term medication use by Markov analysis: beyond persistence. BMC Health Serv Res 7 (2007) 106
29. Krishnan J.A., Riekert K.A., McCoy J.V., et al. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am J Respir Crit Care Med 170 (2004) 1281-1285
30. Jack B.W., Chetty V.K., Anthony D., et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med 150 (2009) 178-187
31. Almagro P., Barreiro B., Ochoa de Echaguen A., et al. Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. Respiration 73 (2006) 311-317
32. Gudmundsson G., Gislason T., Janson C., et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 26 (2005) 414-419
33. Frey U., and Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet 372 (2008) 1088-1099
34. Watson L., Vonk J.M., Lofdahl C.G., et al. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir Med 100 (2006) 746-753
35. Pauwels R.A. Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 1 (2004) 73-76
36. Breekveldt-Postma N.S., Koerselman J., Erkens J.A., van der Molen T., Lammers J.W., and Herings R.M. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf 17 (2008) 411-422
37. Suissa S., McGhan R., Niewoehner D., and Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 4 (2007) 535-542
38. Kiri V.A., Pride N.B., Soriano J.B., and Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 172 (2005) 460-464
39. Paggiaro P.L., Dahle R., Bakran I., Frith L., Hollingworth K., and Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 351 (1998) 773-780
40. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000) 1297-1303
41. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
42. Sin D.D., and Man S.F. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?. Eur Respir J 21 (2003) 260-266
43. Sin D.D., and Tu J.V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 580-584
44. De Vries F., Pouwels S., Bracke M., et al. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 16 (2007) 612-619
45. Blais L., Ernst P., and Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol 144 (1996) 1161-1169
46. Soriano J.B., Vestbo J., Pride N.B., Kiri V., Maden C., and Maier W.C. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20 (2002) 819-825